Sökning: "Antitumor immunity"
Visar resultat 1 - 5 av 6 avhandlingar innehållade orden Antitumor immunity.
Sammanfattning : CD1d-restricted natural killer T (NKT) lymphocytes are known as potent early regulatory cells of immune responses, acting as a bridge between innate and adaptive immunity. While invariant NKT (iNKT) cells have a protective role in many tumor models, their ability to promote intestinal inflammation, known to enhance intestinal cancer, raised the question if they would be protective in intestinal tumor development. LÄS MER
- Detta är en avhandling från Dept. Tumor Immunology, Immunobiology, BMC, Sölvegatan 19, 223 62, Lund, Sweden
Sammanfattning : Interleukin (IL)-1beta is one of the most pleiotropic and potent cytokines, produced predominantly by activated monocytes and macrophages. IL-1 plays an important role in normal immunoregulatory processes but also in pathophysiological inflammatory responses. In the present study, we developed a model for active IL-1beta secretion. LÄS MER
- Detta är en avhandling från Stockholm : Karolinska Institutet, Department of Oncology-Pathology
Sammanfattning : Ovarian carcinoma is a leading cause of cancer mortality and there is an urgent need for new and better therapeutic modalities that result in improved long-term outcome for this severe malignancy. One promising treatment modality for patients suffering from ovarian carcinoma is immunotherapy. LÄS MER
- Detta är en avhandling från Stockholm : Karolinska Institutet, Microbiology and Tumor Biology Center (MTC)
Sammanfattning : A combined approach of vaccination with β2-microglobulin (β2m)-deficient dendritic cells (DCs) and granulocyte-macrophage colony-stimulating factor (GM-CSF) as a potent adjuvant may link cellular and molecular strategies to further enhance antitumor T-cell responses. T lymphocytes can mediate a potent antitumor immune response. LÄS MER
- Detta är en avhandling från Uppsala : Acta Universitatis Upsaliensis
Sammanfattning : Bacillus Calmette Guérin (BCG), or attenuated Mycobacterium bovis, is the gold standard of immunotherapy in the clinic to treat superficial bladder cancer. However, setbacks remain due to a high recurrence rate, side effects, and BCG-refractory disease. LÄS MER